What's in Store for Zimmer Biomet (ZBH) in Q4 Earnings?
https://www.zacks.com/stock/news/2213563/what-s-in-store-for-zimmer-biomet-zbh-in-q4-earnings?cid=CS-ZC-FT-analyst_blog|earnings_preview-2213563
Jan 22, 2024 - Zimmer Biomet (ZBH) is expected to have gained from the uptake of Persona OsseoTi Keel Tibia for Cementless Knee Replacement in the fourth quarter.
0
TransCode (RNAZ) Down 50% on Issue of New Common Stock
https://www.zacks.com/stock/news/2213010/transcode-rnaz-down-50-on-issue-of-new-common-stock?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2213010
Jan 19, 2024 - TransCode Therapeutics (RNAZ) will issue secondary shares and warrants, diluting its current shareholder base. The company plans to raise $7.5 million in gross proceeds from this issue.
0
ADC Therapeutics (ADCT) Rises 43% in a Month: Here's Why
https://www.zacks.com/stock/news/2213007/adc-therapeutics-adct-rises-43-in-a-month-here-s-why?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2213007
Jan 19, 2024 - ADC Therapeutics (ADCT) surges after it provides business updates that highlight the company's progress with its pipeline. Multiple data readouts are expected throughout this year.
0
Vertex (VRTX), CRSP's Casgevy Gets FDA Nod for Thalassemia
https://www.zacks.com/stock/news/2211622/vertex-vrtx-crsp-s-casgevy-gets-fda-nod-for-thalassemia?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2211622
Jan 17, 2024 - This is the second approval granted to Vertex (VRTX)/CRISPR's (CRSP) gene therapy Casgevy and comes just a month after the FDA approved the therapy for sickle cell disease.
0
Emergent (EBS) Gets $235.8M DoD Contract for Anthrax Vaccine
https://www.zacks.com/stock/news/2209718/emergent-ebs-gets-235-8m-dod-contract-for-anthrax-vaccine?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2209718
Jan 12, 2024 - Emergent (EBS) signs a deal with the U.S. Department of Defense to supply its anthrax vaccine initially for a five-year period, with an option to extend it for another five years.
0
C4 (CCCC) Up 6% on Restructuring Plan to Curb Cash Burn
https://www.zacks.com/stock/news/2209026/c4-cccc-up-6-on-restructuring-plan-to-curb-cash-burn?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2209026
Jan 11, 2024 - The new restructuring plan will allow C4 Therapeutics (CCCC) to extend its cash runway into 2027. The company plans to reduce its workforce by nearly 30%.
0
Biotech Stock Roundup: REGN Down on Eylea Update, MRNA Gains on Preliminary Results
https://www.zacks.com/stock/news/2208960/biotech-stock-roundup-regn-down-on-eylea-update-mrna-gains-on-preliminary-results?cid=CS-ZC-FT-analyst_blog|stock_roundup-2208960
Jan 11, 2024 - Preliminary Q4 and 2023 results from Regeneron (REGN) and Moderna (MRNA) were key highlights this week in the biotech sector.
0
SELLAS (SLS) Rises on FDA Fast Track Tag to Leukemia Candidate
https://www.zacks.com/stock/news/2208400/sellas-sls-rises-on-fda-fast-track-tag-to-leukemia-candidate?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2208400
Jan 10, 2024 - The FDA bestows a Fast Track Designation to SELLAS' (SLS) pipeline candidate, SLS009, for the treatment of relapsed/refractory acute myeloid leukemia. Stock gains.
0
GSK to Buy Private Biotech, Strengthen Respiratory Pipeline
https://www.zacks.com/stock/news/2208092/gsk-to-buy-private-biotech-strengthen-respiratory-pipeline?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2208092
Jan 10, 2024 - GSK's proposed acquisition of Aiolos is set to add the latter's long-acting anti-TSLP monoclonal antibody, AIO-001, to GSK's broad portfolio of respiratory products.
0
Amicus (FOLD) Issues Preliminary Revenue Results for FY23
https://www.zacks.com/stock/news/2206966/amicus-fold-issues-preliminary-revenue-results-for-fy23?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2206966
Jan 08, 2024 - Amicus (FOLD) posts preliminary results for full-year 2023. The company also provides a strategic outlook for 2024.
0